Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Ewa Wrona"'
Autor:
Renata Pacholczak-Madej, Aleksandra Grela-Wojewoda, Mirosława Puskulluoglu, Joanna Lompart, Manuela Las-Jankowska, Katarzyna Krawczak, Ewa Wrona, Lech Zaręba, Justyna Żubrowska, Jerzy Walocha, Stanisława Bazan-Socha, Marek Ziobro
Publikováno v:
Biomedicines, Vol 10, Iss 10, p 2528 (2022)
Nivolumab and ipilimumab combination became the first-line standard in advanced melanoma. We assessed its efficacy in a real-life study in Poland. In a one-year follow-up, we evaluated the medical records of 50 melanoma patients treated with that mod
Externí odkaz:
https://doaj.org/article/b5cf9ecd12f24219ba5cbad3ce0cc533
Autor:
Ewa Wrona, Sylwia Dębska-Szmich, Marta Pastuszka, Marcin Braun, Rafał Czyżykowski, Piotr Potemski
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
In up to 34% of cases, thymoma, itself a rare neoplasm, is accompanied by autoimmune disorders, two of which are thymoma-associated multiorgan autoimmunity (TAMA) and paraneoplastic autoimmune multiorgan syndrome (PAMS). Unfortunately, differential d
Externí odkaz:
https://doaj.org/article/957bfb5d47454dcea551bf7e577d8db9
Publikováno v:
International Journal of Molecular Sciences, Vol 22, Iss 11, p 5899 (2021)
CAR-T (chimeric antigen receptor T) cells have emerged as a milestone in the treatment of patients with refractory B-cell neoplasms. However, despite having unprecedented efficacy against hematological malignancies, the treatment is far from flawless
Externí odkaz:
https://doaj.org/article/795a085b6c924c3f8896eeb207e03e09
Autor:
Marcin Braun, Bartlomiej Tomasik, Ewa Wrona, Wojciech Fendler, Przemyslawa Jarosz-Chobot, Agnieszka Szadkowska, Agnieszka Zmysłowska, Jayne Wilson, Wojciech Mlynarski
Publikováno v:
Journal of Diabetes Research, Vol 2016 (2016)
Introduction. It remains unclear how HbA1c recommendations influence metabolic control of paediatric patients with type 1 diabetes mellitus. To evaluate this we compared reported HbA1c with guideline thresholds. Materials and Methods. We searched sys
Externí odkaz:
https://doaj.org/article/d69d391f357548729aee4dca75ed9fad
Autor:
Jagoda Jakubik, Alicja Majos, Dorota Jesionek‑kupnicka, Ewa Wrona, Agnieszka Kaufman‑szymczyk, Katarzyna Lubecka‑gajewska, Jaroslaw Jakubik
Publikováno v:
Oncology Letters. 25
Autor:
Piotr Potemski, Ewa Wrona
Publikováno v:
Oncology in Clinical Practice. 15:202-207
Robust research over the past 30 years has led recently to the first approval of genetically enhanced T lymphocytes expressing chimeric antigen receptors (CAR T-cells) as a tool to fight cancer. The backbone of the aforementioned therapy is to equip
Autor:
Marcin Braun, Agata Pastorczak, Joanna Taha, Wojciech Fendler, Jerzy Kowalczyk, Monika Lejman, Wojciech Młynarski, Ewa Wrona
Publikováno v:
Journal of Applied Genetics
Chromosome 21 abnormalities are the most frequent genetic findings in childhood B cell precursor acute lymphoblastic leukemia (BCP-ALL) cases. Majority of patients are effectively diagnosed with fluorescence in situ hybridization (FISH) and karyotypi
Autor:
Sylwia Dębska-Szmich, Rafał Czyżykowski, Ewa Wrona, Marta Pastuszka, Marcin Braun, Piotr Potemski
Publikováno v:
Frontiers in Immunology
Frontiers in Immunology, Vol 12 (2021)
Frontiers in Immunology, Vol 12 (2021)
In up to 34% of cases, thymoma, itself a rare neoplasm, is accompanied by autoimmune disorders, two of which are thymoma-associated multiorgan autoimmunity (TAMA) and paraneoplastic autoimmune multiorgan syndrome (PAMS). Unfortunately, differential d
Publikováno v:
Archivum Immunologiae et Therapiae Experimentalis
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive, treatment-resistant cancer. Five-year survival rate is about 9%, one of the lowest among all solid tumors. Such a poor outcome is partly due to the limited knowledge of tumor biology, an
Autor:
Joanna Madzio, Bartlomiej Pawlik, Jerzy Kowalczyk, Łukasz Sędek, Ewa Wrona, Wojciech Młynarski, Monika Lejman, Tomasz Szczepański, Agata Pastorczak, Justyna Jakubowska
Publikováno v:
Oncology Letters.
Resistance to L-asparaginase (L-asp) is a major contributor to poor treatment outcomes of several subtypes of childhood B cell precursor acute lymphoblastic leukemia (BCP-ALL). Asparagine synthetase (ASNS), legumain (LGMN) and cathepsin B (CTSB) serv